Vyome Q2 Loss Widens to $719K; FDA Seeks More Data on VT-1953

summarizeSummary

Vyome's Q2 loss widened on higher R&D spending, while the FDA asked for more data on its lead drug candidate and Indian tax authorities issued a $750,000 demand order.

check_boxKey Events · Earnings and Guidance · HIND

• Q2 Net Loss Widens

  Net loss of $719,683 in Q2 2026 vs $308,760 in Q2 2025, driven by R&D expenses rising to $506,723 from $80,061.

• Cash Runway at 15 Months

  Cash balance of $7,887,510 as of June 30, 2026, sufficient to fund operations for at least 15 months including initiation of the VT-1953 pivotal trial.

• FDA Requests More Data on VT-1953

  FDA sent written correspondence requesting additional information and clarifications on the Orphan Drug Designation application for VT-1953 filed in January 2026.

• GST Demand Order of $750K

  Indian GST authorities issued a demand order of approximately $750,000 including interest and penalty; company is contesting in Delhi High Court and has not recorded a liability.

auto_awesomeAnalysis · HIND · Life Sciences

A widening quarterly loss at Vyome Holdings underscores the cost of advancing its lead drug candidate. The company reported a Q2 2026 net loss of $719,683, more than double the $308,760 loss a year ago, driven by a six-fold increase in R&D spending to $506,723. Cash stands at $7.9 million, enough for at least 15 months of operations. Meanwhile, the FDA requested additional information on the Orphan Drug Designation application for VT-1953, a regulatory step that could delay the program. Separately, Indian tax authorities issued a $750,000 GST demand order, which the company is contesting in court.